{"id":542960,"date":"2021-05-12T19:22:01","date_gmt":"2021-05-12T19:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542960"},"modified":"2021-05-12T19:22:01","modified_gmt":"2021-05-12T19:22:01","slug":"cold-agglutinin-disease-cad-market-analysis-market-size-epidemiology-trends-leading-companies-and-therapies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cold-agglutinin-disease-cad-market-analysis-market-size-epidemiology-trends-leading-companies-and-therapies-by-delveinsight_542960.html","title":{"rendered":"Cold Agglutinin Disease (CAD) Market Analysis, Market Size, Epidemiology, Trends, Leading Companies And Therapies By DelveInsight"},"content":{"rendered":"
\"Cold<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cCold Agglutinin Disease (CAD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the  Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the  Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to a survey, reported a large series of CAD cases where the study identified that 68% of cases belonged to primary CAD and 32% belonged to secondary CAD. Causes of secondary CAD were as follows: B-cell lymphoma, T-cell lymphoma, an auto-immune disorder.<\/p>\n<\/li>\n

  2. \n

    Berentsen et al. suggested a prevalence of 16.2 cases per million and an incidence rate of 1.0 CAD cases per million people per year in the Norwegian population. More than 70% of new cases are seen annually in patients above 40 years of age. The peak incidence being between 60 and 70 years of age with a median age of onset at 67 years. <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Cold Agglutinin Disease (CAD) market report covers a descriptive overview and comprehensive insight of the Cold Agglutinin Disease (CAD) epidemiology and Cold Agglutinin Disease (CAD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Cold Agglutinin Disease (CAD) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Cold Agglutinin Disease (CAD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Cold Agglutinin Disease (CAD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease (CAD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Cold Agglutinin Disease (CAD): Overview<\/strong><\/p>\n

    Cold agglutinin disease (CAD) is a condition that makes your body’s immune system attack your red blood cells and destroy them. It’s triggered by cold temperatures, and it can cause problems that range from dizziness to heart failure. It’s also called cold antibody hemolytic anemia.<\/p>\n

    The key players involved in Cold Agglutinin Disease (CAD) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      Sanofi<\/p>\n<\/li>\n

    2. \n

      Apellis Pharmaceuticals<\/p>\n<\/li>\n

    3. \n

      Janssen Pharmaceutical<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Cold Agglutinin Disease (CAD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Sutimlimab<\/p>\n<\/li>\n

      2. \n

        APL-2<\/p>\n<\/li>\n

      3. \n

        Bortezomib<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Cold Agglutinin Disease (CAD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Cold Agglutinin Disease (CAD) Market Overview at a Glance<\/p>\n

        6. Cold Agglutinin Disease (CAD) Disease Background and Overview<\/p>\n

        7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Cold Agglutinin Disease (CAD)<\/p>\n

        9. Cold Agglutinin Disease (CAD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Cold Agglutinin Disease (CAD) Emerging Therapies<\/p>\n

        12. Cold Agglutinin Disease (CAD) Market Outlook<\/p>\n

        13. Country-Wise Cold Agglutinin Disease (CAD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Cold Agglutinin Disease (CAD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Cold Agglutinin Disease (CAD)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Cold Agglutinin Disease (CAD) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Cold Agglutinin Disease (CAD) market. A detailed picture of the  Cold Agglutinin Disease (CAD) pipeline landscape is provided, which includes the disease overview and  Cold Agglutinin Disease (CAD) treatment guidelines.<\/p>\n

        Cold Agglutinin Disease (CAD) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Cold Agglutinin Disease (CAD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cold Agglutinin Disease (CAD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cCold Agglutinin Disease (CAD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542960","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542960"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}